Mereo BioPharma Group plc
MREO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.28 | 0.01 | -0.14 |
| FCF Yield | -6.48% | -7.07% | -42.92% | -3.09% |
| EV / EBITDA | -10.70 | -9.72 | -1.12 | -21.83 |
| Quality | ||||
| ROIC | -68.89% | -48.40% | -55.05% | -16.34% |
| Gross Margin | 0.00% | 74.26% | 37.89% | 50.89% |
| Cash Conversion Ratio | 0.76 | 0.72 | 1.16 | -0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -41.21% | – | – |
| Free Cash Flow Growth | -55.60% | 44.50% | -572.50% | 79.64% |
| Safety | ||||
| Net Debt / EBITDA | 1.49 | 1.98 | 1.04 | 15.50 |
| Interest Coverage | -34.56 | -9.86 | -12.96 | -4.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.35 | -9.84 |
| Cash Conversion Cycle | -818.22 | -196.45 | -1,738.12 | -69.46 |